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In the last decade, near-infrared spectroscopy
(NIRS) has taken an important place in the
industrial field, especially in the pharma-
ceutical industry. Indeed, this technique, 
which belongs to vibrational spectroscopy,
shows numerous advantages including fast
acquisition, non-invasive, non-destructive and
minimisation of sample preparation and offers
the possibility to use probes. Furthermore, this
solvent-free technique is a promising tool in
Process Analytical Technology (PAT) and Green
Chemistry frameworks. 
As any analytical procedures, NIRS quanti -
tative methods require a thorough validation
before their applications in the pharmaceutical
industry. Several notes and drafts for guidance
were published by different industrial or
scientist groups and regulatory authorities in
order to help analysts to decide if their
quantitative methods are valid1-4. Despite these
publications, a lack of thorough validation of
NIRS methods remains in literature. 
Facing this situation, the objective of this
review is to provide a new tool which offers
analysts the possibility of having a critical
overview of methodologies applied to assess
the validity of quantitative methods using near-
infrared spectroscopy. This review is oriented in
pharmaceutical applications. 
Decision methodologies used to
validate NIRS methods
There are four main decision method-
ologies used to assess the validity of analytical 
methods, namely the descriptive approach
As in any analytical method, a mandatory step at the end of the development of a
near infrared spectroscopy (NIRS) method is the validation. This step ensures that
future results coming from the application of the method in routine will be 
close enough to the true value. However, from the literature, a minority of 
NIRS methods are thoroughly validated despite the guidelines published by 
different group and regulatory authorities to help an analyst adequately decide 
if his method can be considered as valid. In this context, the aim of this review is to
offer a critical overview of the different validation methodologies applied to assess
the validity of quantitative methods using near infrared spectroscopy used in the
field of pharmacy.
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using statistical descriptive parameters, 
the different approach using statistical
hypothesis tests, the equivalence app-
roach and the accuracy profile which is 
based on the statistical methodology of
tolerance intervals5-8.
Most of the validation procedures 
per formed for NIRS methods in pharmaceutical
applications fall in the descriptive approach
which includes two main meth odologies: the
use of traditional chemometric parameters and
the criteria from the ICH Q2 guideline9.
Concerning traditional chemometric
parameters, two steps are involved to validate 
a multivariate calibration model. The first 
step entails the use of a calibration set of 
data and using the cross-validation technique
such as leave-one-out to assess the suitability 
of the R 2cal, the root mean square error of
calibration (RMSEC) and the root mean square
error of the cross-validation (RMSECV) are
computed. To optimise this calibration model, 
it is necessary to determine the optimal number
of factors by plotting RMSEC and more
especially RMSECV versus the number of factors.
The RMSEC is decreased by increasing the
number of factors and it also provides the most
optimistic estimate of the partial least squares
(PLS) calibration model performance showing
the ability of this multivariate calibration 
model to fit the observed data of the calibration
set. The second step consists of the use of an
external set of data, not involved in the
calibration procedure, to validate the NIR
predictive model on future data. The R 2pred 
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Figure 1 Accuracy profile obtained from an NIR method for the determination of an API in pharmaceutical tablets.
The plain line is the relative bias, the dashed lines are the β-expectation tolerance limits (β=95 per cent) and the
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Today, many companies are not 
only striving to manufacture high 
quality products, but also increase 
production efficiency by installing the 
analytical systems directly into their 
production plants. This improves  
process verifiability and process  
understanding and gives the company 
the opportunity to optimize material 
use, run-time of machines and quality 
of the products up to real-time-release.
Bruker´s spectroscopical technology 
based on modern FT spectrometers 
can be used at a lot of different 
process steps and offer high amount 
information to gain better process 
knowledge. The robust design of 
all spectrometers enables usage in 
tough conditions in production plants 
with very low maintenance costs/
times.
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and the root mean square error of prediction (RMSEP) are used to
evaluate the quantitative performance of the NIR model. At the end
of this process, it is advised to readjust the number of factors in order
to improve the performance of the developed NIR model by
observing the criteria values. In this context, the closer to one of the
value of R 2cal and R
2
pred are and the smaller the values of RMSEC,
RMSECV and RMSEP are, better is the developed NIR method.  
The problem of the traditional chemometric validation
application in literature is that, most of the time, there is no evaluation
of quantitative criteria which are trueness, precision, results accuracy,
linearity and valid dosing range. Therefore, the pharmaceutical
regulatory requirements concerning method validation found in the
ICH Q2 document are not always respected9. In addition, there is no
information about the suitability of the method for its intended use or
evaluation of the future results and their reliability coming from the
future application of the NIR method in routine. 
The second main approach used to validate a NIR multivariate
quantitative method is the use of validation criteria found in the ICH
Q2 document9. The main limitation of this validation methodology
concerns the evaluation of the linearity which is the relationship
between the predicted results coming from the NIRS and the
reference results obtained by a reference method (e.g. HPLC). Indeed,
the linearity is evaluated by observing the value of the correlation
coefficient: the closer to one its value is, the better the results are.
However, it has been demonstrated that a value close to one is not
sufficient to guarantee the comparability and the exchangeability of
the analytical method investigated10. 
What about the differential approach, where statistical
hypothesis tests are used to assess if the observed effects are
statistically significant. This approach is generally used to evaluate if
the average difference of the results coming from the reference 
and the NIRS methods are statistically different in order to evaluate
the average accuracy of the method. But it is also used to assess the
linearity criterion by demonstrating that the slope is equal to one and
the intercept equal to zero. However, there is an important risk with
this approach, to accept a method as valid even though it is not. It is
important to avoid flawed conclusions. The only conclusion that can
be drawn with this approach is the ability to demonstrate a difference
and not equivalence. The equivalence approach, which is not as well
used, corrects these flaws. 
The last approach is the accuracy profile based on tolerance
intervals. The tolerance interval used is a ‘β-expectation tolerance
interval’ which defines an interval where an expected proportion of
NIR results will fall with a defined probability β. An example of an
accuracy profile is given in Figure 1 opposite. 
In this representation, the plain line represents the relative bias
and the dashed lines are the β-expectation tolerance limits which
links β-expectation tolerance intervals calculated from each
concentration levels tested using their estimated bias and standard
deviation of intermediate precision. If β-expectation tolerance limits
are comprised within the acceptance limits, which are represented 
in dotted lines and fixed according to the regulatory requirements 
(five per cent on pharmaceutical specialties), the method can be
considered as valid on the whole concentration range. This fully ICH
compliant approach can declare the method as valid and guarantees
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the quality, reliability and accuracy of the
individual results for the intended use of 
the NIRS method. Accuracy profiles have 
been computed from results coming from some
NIRS applications validated according to the
descriptive approach. It has been shown that
some of them which present low RMSEP could
not be declared as valid based on their accuracy
profiles11. This case demonstrates that small
RMSEP is not sufficient to guarantee the validity
of NIRS methods. 
Conclusion
The consideration of an analytical method as
valid depends on the responsibility of the
analyst and of the methodology which he
chooses to make this conclusion. This review
serves to highlight that it is important to avoid
flawed conclusions. Some approaches are not
sufficient to consider a NIRS method as valid. The
accuracy profile approach which is based on
tolerance interval is probably more adapted and
is fully ICH compliant.
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